Deals
Deal activity by volume related to artificial intelligence decreased by 25% year-on-year in 2022 in the pharmaceutical industry
Credit: Bert van Dijk/Getty images.
Powered by
Analysis of the key themes driving deal activity reveals that artificial intelligence accounted for 1,253 pharmaceutical deals between 2018 and 2022, worth a total value of $77,544m, according to GlobalData’s Deals database covering mergers and acquisitions, private equity, venture financing, equity offerings and partnerships. The $6,000m acquisition of Nimbus Lakshmi by Takeda Pharmaceutical was the largest disclosed deal in 2022, while the $1,600m licensing agreement between Astellas Pharma and Dyno Therapeutics was the largest disclosed deal in 2021.
In volume terms, artificial intelligence related deal activity decreased by 25% year-on-year in 2022 and increased by 23% year-on-year in 2021.
Deal activity related to artificial intelligence in the global pharmaceutical industry in the last five years
Top deals related to artificial intelligence in the pharmaceutical industry in the last five years
Deal volume by deal type for artificial intelligence related deals in the pharmaceutical industry in the last five years
Venture financing accounted for the highest number of deals in the last five years, with 496 deals, followed by partnership (479 deals), and equity offering (116 deals).
Top financial advisors for artificial intelligence related deals by value in the pharmaceutical industry in the last five years
The top financial advisors supporting deals related to artificial intelligence in the pharmaceutical industry in the last five years in terms of value were Goldman Sachs, UBS Group, J.P. Morgan Securities, Evercore Group, and Morgan Stanley.
Top legal advisors for artificial intelligence related deals by value in the pharmaceutical industry in the last five years
The top legal advisors supporting deals related to artificial intelligence in the pharmaceutical industry in the last five years in terms of value were Latham & Watkins, Clifford Chance, Hengeler Mueller, Slaughter and May, and Wachtell, Lipton, Rosen & Katz.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Deals database provides comprehensive coverage across industries tracking market activity of global mergers & acquisitions, including asset acquisitions/divestments; private equity deals (PE); venture finance deals (VC); equity offerings, including IPOs, follow-on offerings, and private placements; debt offerings, including private placements, ESG bonds and loans; partnerships; and licensing agreements.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumored deals.
